Article Excerpt
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
…companies in the SynBio space are developing increasingly reliable ways of engineering cells, producing disease models and creating robust biological paradigms.
Starting From The Ground Up
Take for example Molecular Assemblies, Inc., a San Diego-based startup. The company has developed a DNA synthesis technology that the company’s chief technology officer, Phil Paik, says can produce longer chains of DNA with higher accuracy than currently used chemical-based synthesis.
To read the full article, click here.
